Tuberc Respir Dis.
2025 Apr;88(2):193-215. 10.4046/trd.2024.0198.
International Severe Asthma Registry (ISAR): 2017–2024 Status and Progress Update
- Larenas-Linnemann D
1 - Rhee CK2
- Altraja A3
- Busby J4
- Tran TN5
- Wang E6,7
- Popov TA8
- Mitchell PD9
- Pfeffer PE10,11
- Pleasants RA12,13
- Katial R6
- Koh MS14,15
- Bourdin A16
- Schleich F17
- Máspero J18,19
- Hew M20,21
- Peters MJ22,23
- Jackson DJ24
- Christoff GC25
- Perez-de-Llano L26,27
- Cherrez- Ojeda I28,29,30,3
- Fonseca JA32
- Costello RW33
- Torres-Duque CA34,35
- Kuna P36
- Menzies-Gow AN37,38
- Stjepanovic N39
- Gibson PG40,41
- Pitrez PM42
- Bergeron C43,44
- Porsbjerg CM45
- Taillé C46
- Taube C47
- Papadopoulos NG48,49
- Papaioannou AI50
- Salvi S51
- Canonica GW52,53
- Heffler E52,53
- Iwanaga T54
- Al-Ahmad MS55,56
- Lehmann S57,58
- Al-Lehebi R59,60
- Cosio BG61
- Perng DW62,63
- Mahboub B64,65
- Heaney LG66
- Patel PH67
- Lugogo N68
- Wechsler ME69
- Bulathsinhala L70,71
- Carter V70,71
- Fletton K70,71
- Neil DL70,71
- Scelo G70,71
- Price DB70,71,72
- Affiliations
-
- 1Center of Excellence in Asthma and Allergy, Médica Sur Hospital, Mexico City, Mexico
- 2Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
- 3Department of Pulmonology, Lung Clinic, Tartu University Hospital, University of Tartu, Tartu, Estonia
- 4Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK
- 5BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA
- 6Division of Allergy and Clinical Immunology, Department of Medicine, National Jewish Health, Denver, CO, USA
- 7Division of Allergy and Clinical Immunology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA
- 8University Hospital St. Ivan Rilski, Sofia, Bulgaria
- 9School of Medicine, Trinity College Dublin, Dublin, Ireland
- 10Department of Respiratory Medicine, Barts Health NHS (National Health Services) Trust, London, UK
- 11William Harvey Research Institute, Queen Mary University of London, London, UK
- 12Marsico Lung Institute, University of North Carolina, Chapel Hill, NC, USA
- 13Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA
- 14Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore
- 15Duke-National University, Singapore Medical School, Singapore
- 16PhyMedExp, University of Montpellier, CNRS (National Center for Scientific Research), INSERM (The National Institute of Health and Medical Research), CHU (Centre Hospitalier Universitaire), Montpellier, France
- 17Department of Pneumology, University Hospital of Liège, GIGA I3 Research Group, Exercise Physiology Lab, Department of Physical Activity and Rehabilitation Sciences, University of Liège, Liège, Belgium
- 18Clinical Research for Allergy and Respiratory Medicine, CIDEA Foundation, Buenos Aires, Argentina
- 19University Career of Specialists in Allergy and Clinical Immunology at the Buenos Aires University School of Medicine, Buenos Aires, Argentina
- 20Allergy, Asthma & Clinical Immunology Service, Alfred Health, Melbourne, VIC
- 21Public Health and Preventive Medicine, Monash University, Melbourne, VIC
- 22Department of Thoracic Medicine, Concord Hospital, Sydney, NSW
- 23Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia
- 24Guy’s Severe Asthma Centre, School of Immunology & Microbial Sciences, King’s College London, London, UK
- 25Faculty of Public Health, Medical University, Sofia, Bulgaria
- 26Pneumology Service, Lucus Augusti University Hospital, EOXI Lugo, Monforte, Cervo
- 27Department of Psychiatry, Radiology, Public Health, Nursery and Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain
- 28Holy Spirit University, Samborondon, Ecuador
- 29The Institute of Allergology, Charité – Berlin University Medicine, Berlin, Germany
- 30The Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany
- 31Respiralab Research Group, Guayaquil, Ecuador
- 32CINTESIS@RISE (Center for Health Technology and Services Research at Health Research Network), MEDCIDS (Departamento Medicina da Comunidade, Informação e Decisão em Saúde/Department of Community Medicine, Information and Health Decisions), Faculty of Medicine of the University of Porto, Porto, Portugal
- 33Clinical Research Centre, Smurfit Building Beaumont Hospital, Department of Respiratory Medicine, RCSI (Royal College of Surgeons Ireland), Dublin, Ireland
- 34CINEUMO (Centro Internacional de Investigación en Neumología), Respiratory Research Center, Fundación Neumológica Colombiana, Bogotá, Colombia
- 35Doctoral Biosciences, Universidad de La Sabana, Chia, Colombia
- 36Division of Internal Medicine Asthma and Allergy, Medical University of Lodz, Lodz, Poland
- 37BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK
- 38Lung Division, Royal Brompton & Harefield Hospital, London, UK
- 39BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden
- 40Australian Severe Asthma Network, Priority Research Centre for Healthy Lungs, University of Newcastle, Newcastle, NSW, Australia
- 41Hunter Medical Research Institute, Department of Respiratory and Sleep Medicine, John Hunter Hospital, New Lambton Heights, NSW, Australia
- 42Pulmonology Division, Hospital Santa Casa de Porto Alegre, Porto Alegre, Brazil
- 43Department of Medicine, Centre for Lung Health, Vancouver General Hospital, Vancouver, BC, Canada
- 44Department of Medicine, The University of British Columbia, Vancouver, BC, Canada
- 45Department of Respiratory Medicine and Infectious Diseases, Research Unit, Bispebjerg Hospital, Copenhagen, Denmark
- 46Department of Respiratory Diseases, Bichat Hospital, AP-HP (L'Assistance Publique – Hôpitaux de Paris), Nord-Université Paris Cité; Paris, France
- 47Department of Pulmonary Medicine, University Medical Center Essen-Ruhrlandklinik, Essen, Germany
- 48Division of Infection, Immunity & Respiratory Medicine, University of Manchester, Manchester, UK
- 49Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece
- 502nd Respiratory Medicine Department, National and Kapodistrian University of Athens Medical School, Attikon University Hospital, Athens, Greece
- 51Pulmocare Research and Education Foundation, Pune, India
- 52Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Rozzano, Italy
- 53Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
- 54Sleep Medicine Centre, Kindai University Hospital, Osakasayama, Japan
- 55Microbiology Department, College of Medicine, Kuwait University, Kuwait City, Kuwait
- 56Al-Rashed Allergy Center, Ministry of Health, Kuwait City, Kuwait
- 57Section of Thoracic Medicine, Department of Clinical Science, University of Bergen, Bergen, Norway
- 58Department of Thoracic Medicine, Haukeland University Hospital, Bergen, Norway
- 59Department of Pulmonology, King Fahad Medical City, Riyadh, Saudi Arabia
- 60College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
- 61Son Espases University Hospital-IdISBa (Institut d’Investigació Sanitària Illes Balears)-Ciberes, Mallorca, Spain
- 62School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
- 63Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
- 64Rashid Hospital, Dubai Health (DH), Dubai, United Arab Emirates
- 65College of Medicine, University of Sharjah, Sharjah, United Arab Emirates
- 66Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, Belfast, UK
- 67Respiratory Medicine, Royal Brompton Hospital, London, UK
- 68Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA
- 69Department of Medicine, National Jewish Health Cohen Family Asthma Institute, National Jewish Health, Denver, CO, USA
- 70Observational and Pragmatic Research Institute, Singapore, Singapore, 71Optimum Patient Care Global, Cambridge, UK
- 71Optimum Patient Care Global, Cambridge, UK
- 72Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK
- KMID: 2566177
- DOI: http://doi.org/10.4046/trd.2024.0198
Abstract
- The International Severe Asthma Registry (ISAR) was established in 2017 to advance the understanding of severe asthma and its management, thereby improving patient care worldwide. As the first global registry for adults with severe asthma, ISAR enabled individual registries to standardize and pool their data, creating a comprehensive, harmonized dataset with sufficient statistical power to address key research questions and knowledge gaps. Today, ISAR is the largest repository of real-world data on severe asthma, curating data on nearly 35,000 patients from 28 countries worldwide, and has become a leading contributor to severe asthma research. Research using ISAR data has provided valuable insights on the characteristics of severe asthma, its burdens and risk factors, real-world treatment effectiveness, and barriers to specialist care, which are collectively informing improved asthma management. Besides changing clinical thinking via research, ISAR aims to advance real-world practice through initiatives that improve registry data quality and severe asthma care. In 2024, ISAR refined essential research variables to enhance data quality and launched a web-based data acquisition and reporting system (QISAR), which integrates data collection with clinical consultations and enables longitudinal data tracking at patient, center, and population levels. Quality improvement priorities include collecting standardized data during consultations and tracking and optimizing patient journeys via QISAR and integrating primary/secondary care pathways to expedite specialist severe asthma management and facilitate clinical trial recruitment. ISAR envisions a future in which timely specialist referral and initiation of biologic therapy can obviate long-term systemic corticosteroid use and enable more patients to achieve remission.
